Pronunciation: meth-skoe-PAHL-uh-meen BRO-mide
Class: Quarternary anticholinergic
- Tablets 2.5 mg
- Tablets 5 mg
Competitively inhibits action of acetylcholine at muscarinic receptor.
Poorly and unreliably absorbed (10% to 25%).
Primarily in urine and bile as well as unabsorbed drug in the feces.
4 to 6 h.
Indications and Usage
Adjunctive treatment of peptic ulcer.
Glaucoma; obstructive uropathy (eg, bladder neck obstruction); obstructive disease of the GI tract (eg, pyloroduodenal stenosis); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable CV status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis; hypersensitivity to any component of the drug.
Dosage and AdministrationAdults
PO 2.5 mg one-half h before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg every day will be clinically effective in most patients. In patients experiencing severe abdominal pain or cramping or symptoms that demand prompt relief, methscopolamine may be started at 20 mg every day, administered in doses of 5 mg one-half h before meals and at bedtime.
Store at controlled room temperature (59° to 86°F).
May interfere with the absorption of methscopolamine.Antipsychotics, tricyclic antidepressants, drugs with anticholinergic effects
Additive anticholinergic effects may occur.
Laboratory Test Interactions
None well documented.
Headache; nervousness; mental confusion; drowsiness; dizziness; weakness; insomnia.
Decreased sweating; urticaria; other dermal manifestations.
Blurred vision; dilation of pupil; cycloplegia; increased ocular tension; loss of taste.
Nausea; vomiting; constipation; bloated feeling.
Impotence; suppression of lactation; urinary hesitancy and retention.
Severe allergic reaction; drug idiosyncrasies including anaphylaxis; xerostomia.
Category C .
Safety and efficacy not established.
Special Risk Patients
Use with caution in the elderly and in all patients with autonomic neuropathy, hepatic or renal disease, ulcerative colitis (large doses may produce paralytic ileus, precipitating or aggravating toxic megacolon), hyperthyroidism, coronary heart disease, CHF, tachyrhythmia, tachycardia, hypertension, or prostatic hypertrophy.
May be a symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. Treatment of diarrhea with drug is inappropriate and possibly harmful.
Can occur in presence of high environmental temperature.
CNS disturbances (from restlessness and excitement to psychotic behavior), circulatory changes (flushing, fall in BP, circulatory failure), respiratory failure, paralysis, coma.
- Advise patient to take prescribed dose 30 min before meals and at bedtime.
- Advise patient that dose may be changed periodically to achieve max benefit.
- Advise patient to avoid strenuous activity during periods of high temperature or humidity.
- Advise patient to take sips of water, suck on ice chips or sugarless hard candy, or chew sugarless gum if dry mouth occurs.
- Advise patient that drug may cause drowsiness or blurred vision and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
- Advise patient to notify health care provider if symptoms do not improve or appear to be getting worse.
- Advise patient to stop taking the drug and notify health care provider immediately if any of the following occur: rash, flushing, eye pain, inability to urinate.
- Advise patient that medication may cause dry mouth, urination difficulties, or constipation and to notify health care provider if they occur and are bothersome.
Copyright © 2009 Wolters Kluwer Health.
More about methscopolamine
- Other brands: Pamine